Gamma-aminobutyric acid type A receptor subunit beta-3 (GABAA receptor β3 subunit (GABRB3))

The **gamma‑aminobutyric acid type A receptor subunit beta‑3** is a component of the pentameric ligand-gated chloride channels known as **GABA(A) receptors**, which mediate fast inhibitory neurotransmission throughout the central nervous system. The β3 subunit contributes to forming functional heteropentameric channels that open upon binding gamma‑aminobutyric acid—the main inhibitory neurotransmitter—allowing chloride ions into neurons and resulting in membrane hyperpolarization. The structure and function of these receptors underlie their critical role in regulating neuronal excitability and maintaining CNS homeostasis. The β3-containing isoforms are widely distributed across brain regions including cortex and hippocampus[5]. Mutations or altered expression have been linked to epilepsy, neurodevelopmental disorders such as autism spectrum disorder, Angelman syndrome, Prader-Willi syndrome, and other neurological conditions[2][5]. Drugs acting on these receptors—including benzodiazepines and barbiturates—are used clinically for their anxiolytic, sedative-hypnotic, anticonvulsant properties but carry risks related to CNS depression and dependence[1][2].

Other names

GABA(A) receptor beta-3 subunitGABRB3Gamma-aminobutyric acid receptor subunit beta-3

Drugs targeting this molecule typically act by modulating chloride ion flow through the channel upon binding of gamma‑aminobutyric acid. This results in hyperpolarization of neurons and inhibition of action potential firing. Positive allosteric modulators like benzodiazepines enhance this inhibitory effect[1][2].